71939-50-9 双氢青蒿素

运输信息：冰袋运输。危险描述：非危险化学品，WGK Germany:2，RTECS号:KD4165550，海关编码:29329990，存储类别:5.2 - 有机过氧化物质和自反应危险物质，危险性类别:危害水生环境-长期危害 类别2，有机过氧化物 C型

双氢青蒿素是青蒿素衍生物，作为抗疟药用于各型疟疾，尤其对抗氯喹、哌喹耐药的脑型、凶险型恶性疟的抢救；还具有抗银屑病、抗炎作用。

医药

合成路线 1

• 步骤: 在氮气保护下，将LiBHEt₃溶液（1M的THF溶液）通过注射器缓慢滴加到青蒿素（200mg，0.71mmol）溶解于无水THF（20mL）的溶液中；通过TLC监测反应至青蒿素完全消耗（约5-10分钟）；分批加入乙酸的THF溶液（20体积%，每次100μL或50μL）淬灭反应，调节pH至5-6；减压浓缩至干；用乙酸乙酯和蒸馏水萃取，水相再用乙酸乙酯萃取两次，合并有机相，无水硫酸钠干燥6小时，过滤后减压浓缩至干，得白色片状产物。
• 条件: 2℃；0.17小时；惰性气氛（N₂）；流动反应器
• 产率: 94%
• 参考文献: [1] Molecules, 2011, vol. 16, # 6, p. 4527-4538；[2] Journal of the Chemical Society. Perkin Transactions 1, 2001, # 19, p. 2421-2429；[3] Patent: WO2013/38206, 2013, A1. Location in patent: Paragraph 10; 11；[4] Journal of the American Chemical Society, 2011, vol. 133, # 7, p. 2076-2079；[5] Organic Process Research and Development, 2007, vol. 11, # 3, p. 336-340；[6] Chemical Biology and Drug Design, 2017, vol. 90, # 5, p. 1019-1028；[7] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 13, p. 2275-2278；[8] Heterocycles, 1994, vol. 39, # 2, p. 649-656；[9] Journal of Medicinal Chemistry, 2012, vol. 55, # 17, p. 7892-7899；[10] RSC Advances, 2015, vol. 5, # 59, p. 47959-47974；[11] Phytochemistry, 1996, vol. 41, # 1, p. 97-104；[12] Molecules, 2013, vol. 18, # 3, p. 2864-2877；[13] Medicinal Chemistry Research, 2010, vol. 19, # 6, p. 524-532；[14] Journal of Medicinal Chemistry, 1987, vol. 30, # 11, p. 2147-2150；[15] Synlett, 2008, # 19, p. 3053-3057；[16] Patent: CN108586480, 2018, A. Location in patent: Paragraph 0035; 0039；[17] Indian Journal of Chemistry - Section B Organic Chemistry Including Medicinal Chemistry, 1989, vol. 28, # 9, p. 751-754；[18] Collection of Czechoslovak Chemical Communications, 1991, vol. 56, # 5, p. 1037-1041；[19] Phytochemistry (Elsevier), 1993, vol. 33, # 4, p. 821-826；[20] Journal of Medicinal Chemistry, 1997, vol. 40, # 9, p. 1396-1400；[21] Tetrahedron, 1997, vol. 53, # 22, p. 7493-7500；[22] Bioorganic and Medicinal Chemistry, 2000, vol. 8, # 6, p. 1361-1370；[23] Journal of the Indian Chemical Society, 2001, vol. 78, # 9, p. 489-491；[24] Tetrahedron Letters, 2002, vol. 43, # 40, p. 7235-7237；[25] Patent: WO2004/50662, 2004, A1. Location in patent: Page 7；[26] Patent: WO2004/50662, 2004, A1. Location in patent: Page 7；[27] Patent: WO2004/50662, 2004, A1. Location in patent: Page 8；[28] Patent: WO2004/50662, 2004, A1. Location in patent: Page 7；[29] Patent: WO2004/50662, 2004, A1. Location in patent: Page 8；[30] Patent: WO2004/50662, 2004, A1. Location in patent: Page 8；[31] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 23, p. 7949-7957；[32] Medicinal Chemistry Research, 2012, vol. 21, # 10, p. 3073-3079,7；[33] Archives of Pharmacal Research, 2012, vol. 35, # 9, p. 1525-1531；[34] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 13, p. 3702-3707；[35] Patent: US2013/331581, 2013, A1. Location in patent: Paragraph 0089；[36] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 1, p. 237-239；[37] Catalysis Today, 2014, vol. 239, p. 90-96；[38] Patent: WO2015/7693, 2015, A1. Location in patent: Page/Page column 63；[39] （注：上述来源中部分重复条目已合并）